Pharmaspectra is a leading global provider of medical affairs data to the pharmaceutical and biotech industry. Inflexion invested in Pharmaspectra in 2019, before selling its investment to a NYSE listed trade buyer in 2022.

  • Sector


  • Headquarters

    London, UK

  • Fund


  • Investment date

    October 2019 - July 2022

  • Status


The company

Founded in 2005, Pharmaspectra hosts the world’s largest, continuously updated and integrated online repository of disseminated medical science information. This includes 16 million meeting presentations, 28 million publication abstracts and 417,000 clinical trials results. This data is used across the pharmaceutical sector where Pharmaspectra has an expansive and diverse customer base including 13 of the top 20 pharma companies. The firm has offices in the UK, US, and India.

The Inflexion investment

Inflexion completed the buyout of Pharmaspectra in 2019 through its Enterprise Fund. Under Inflexion’s ownership, substantial investment was made into the growth of Pharmaspectra’s sales team, marketing, and client services as well as in the launch of the company’s new product offering and technology platform.

The Inflexion difference

Inflexion used their extensive experience in scaling and professionalising companies to support Pharmaspectra in their next phase of growth. The digital team worked with the business to create a new medical affairs data and insights platform. Inflexion also supported the international expansion of the business including the build-out of the team in India and developing Pharmaspectra’s market entry strategy into China.

Press releases